GRAIL is a healthcare brand dedicated to detecting cancer early and improving cancer care. They offer the Galleri Test, a groundbreaking multi-cancer early detection (MCED) test that can identify a signal associated with more than 50 types of cancer. The test analyzes cell-free DNA fragments in the bloodstream, looking for abnormal methylation patterns that may indicate the presence of cancer.

By detecting cancer at its early stages, GRAIL aims to increase the chances of successful treatment and potentially cure the disease. Their innovative technology, combined with machine-learning algorithms, enables them to predict the origin of the cancer signal with high accuracy. With a team of leading scientists, engineers, and clinicians, GRAIL is on a mission to transform cancer care and reduce cancer mortality.

Through partnerships and continued research, they strive to bring their innovative technologies to healthcare providers worldwide